

PRESS RELEASE 17.08.21

3P BIOPHARMACEUTICALS ENTERS INTO ALLIANCE WITH PRECIRIX TO DEVELOP PRECISION RADIOPHARMACEUTICALS IN ONCOLOGY

IT'S WITHIN US

3P Biopharmaceuticals enters into alliance with Precirix to develop precision radiopharmaceuticals in oncology

The Spanish CDMO will carry out large-scale manufacturing of single domain antibodies, the backbone of a new product to enter the clinic

Noáin (Spain), and Brussels (Belgium), 16 August 2021 – 3P Biopharmaceuticals S.L.U. (3P), a leading CDMO based in Spain specializing in process development and GMP manufacturing of biological products and Precirix NV, a clinical-stage biotechnology company developing novel radiopharmaceuticals in oncology, have signed an agreement for the clinical manufacturing of a camelid single domain antibody fragment (sdAb), the backbone of Precirix' next product candidate to enter the clinic.

3P Biopharmaceuticals will complete the technology transfer, process upscaling and manufacturing of the mentioned sdAb backbone, as an important first step in advancing this product towards the clinic. Precirix' lead compound, CAM-H2, is already being evaluated in a Phase I/II clinical trial.

The development of precision radiopharmaceuticals, using camelid single-domain antibodies, labeled with radioisotopes, allows radiotherapy to be directed to its specific target, the cancer cell, and deliver the radioactive load in a highly selective manner to the tumor, preventing the radiation from reaching the rest of the body.

Dámaso Molero, Chief Executive Officer of 3P Biopharmaceuticals commented: *"The alliance with Precirix is an exciting new venture for 3P, where, once again, innovation and technology come together making it possible to develop novel drugs against cancer. We look forward to being part of the Precirix journey."*

"This collaboration marks an important step in advancing our second pipeline program towards the clinic. We are confident 3P is the right partner for the manufacturing of our highly selective single domain antibody",
said Ruth Devenyns, Chief Executive Officer of Precirix.

About 3P Biopharmaceuticals

3P Biopharmaceuticals is a market-leading CDMO (Contract Development and Manufacturing Organization) specializing in process development and GMP (Good Manufacturing Practice) manufacturing of biologics and cell therapy products. 3P offers solutions for all manufacturing stages related to new drug development including cell line and process development, analytical methods development, pre-clinical and clinical supply and commercial manufacturing. In its 15-year history, 3P has produced around 60 molecules for more than 50 customers in some 20 countries.

More information: <https://3pbio.com>

About Precirix NV

Precirix is a private, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing precision radiopharmaceuticals, using camelid single-domain antibodies labeled with radioisotopes. The company has a broad pipeline with one product candidate in a Phase I/II clinical trial and two in advanced preclinical stage. Research on multiple isotopes, linker technology and combination therapies further expand the platform. Precirix' technology also allows for a theranostic approach, where patients can be selected using a low dose/imaging version of the product, followed by a higher therapeutic dose for treatment.

More information: <https://www.precirix.com>

FOR FURTHER INFORMATION, PLEASE CONTACT:

Natalia Horstmann

Communications & PR Consultant
+34 608 440091
comunicacion.consultor@3pbio.com

Ruth Devenyns

CEO Precirix
+32 2 479 93 60
info@precirix.com

